ライフサイエンスコーパス: intravesical

1 on bladder nociceptive responses induced by intravesical acetic acid infusion in rats.

2 AN activity were also suppressed (p<0.05) by intravesical administration of 2',3'-0-trinitrophenyl-AT

3 Intravesical administration of 25 and 50 muM oxo-M signi

4 Intravesical administration of 5 muM AMN alone did not a

5 der (10-40 cmH(2)O) was increased 22-100% by intravesical administration of 50 muM oxo-M.

6 Intravesical administration of BCG has been associated w

7 tion was induced by three different stimuli: intravesical administration of either 0.25% acetic acid

8 eractivity that was significantly reduced by intravesical administration of either B1 (des-Arg(10)-Ho

9 or a novel method to treat bladder cancer by intravesical administration of LNP-formulated RNA duplex

10 Intravesical administration of Mycobacterium bovis bacil

11 Intravesical administration of SNAP (2mM) which did not

12 Intravesical administration of targeted nanoparticles ca

13 lished tumor cell masses regressed following intravesical administration of the chemotherapeutic drug

14 Intravesical administration of the mAChR agonist oxotrem

15 These effects were blocked by intravesical administration of the mAChR antagonist atro

16 o be mediated by separate mechanisms because intravesical administration of the pannexin channel anta

17 Within several hours of intravesical administration of these agents, bladder tum

18 ing of human bladder cancer by topical (i.e. intravesical) administration of QD-conjugated anti-CD47.

19 Gemcitabine has substantial activity as an intravesical agent in BCG-refractory TCC and warrants fu

20 e efficacy of gemcitabine administered as an intravesical agent in patients with bacille Calmette-Gue

21 ty profile of gemcitabine administered as an intravesical agent in patients with transitional-cell ca

22 excellent candidate for investigation as an intravesical agent.

23 Up to 50% of patients treated with intravesical agents for superficial bladder cancer will

24 odal therapy (i.e., chemotherapy, radiation, intravesical agents) based on a handful of retrospective

25 ification of patients unlikely to respond to intravesical agents, in whom early cystectomy is advocat

26 ive events) could be induced to discharge by intravesical alpha,beta-meATP (1 mM, 0.1 ml).

27 Intravesical application of alpha,beta-meATP (0.03-1 mM)

28 dence favouring either an extravesical or an intravesical approach.

29 Intravesical bacille Calmette-Guerin (including a mainte

30 ere treated with transurethral resection and intravesical bacillus Calmette Guerin (BCG) therapy and

31 s the standard of care for patients who fail intravesical bacillus Calmette-Guerin (BCG) for nonmuscl

32 developed a systemic illness while receiving intravesical bacillus Calmette-Guerin (BCG) immunotherap

33 Combination therapy with intravesical bacillus Calmette-Guerin (BCG) plus IFN-alp

34 ith superficial bladder cancer refractory to intravesical bacillus Calmette-Guerin (BCG) therapy and

35 non-muscle-invasive BC patients according to intravesical Bacillus Calmette-Guerin (BCG) treatment st

36 Data supports the use of intravesical Bacillus Calmette-Guerin (including a maint

37 The data support the use of intravesical bacillus Calmette-Guerin (including a maint

38 ociated BCG infection who had never received intravesical BCG administration, an epidemiologic study

39 ational use of IFN-alpha in conjunction with intravesical BCG for bladder cancer immunotherapy.

40 gical basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.

41 Intravesical BCG has been used successfully to treat sup

42 ssociated BCG infection who had not received intravesical BCG instillation were selected and the sour

43 l bladder cancer refractory or intolerant to intravesical BCG therapy and refusing a cystectomy were

44 yelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer.

45 ine if p53 status, assessed before and after intravesical BCG therapy, can predict clinical outcome i

46 ients, obtained immediately before and after intravesical BCG therapy.

47 volves complete transurethral resection with intravesical BCG therapy.

48 laining the pulmonary disease resulting from intravesical BCG treatment include a hypersensitivity re

49 induction and maintenance immunotherapy with intravesical BCG vaccine or intravesical chemotherapy.

50 BCG isolates from patients who had received intravesical BCG.

51 Intravesical chemotherapeutic and immunotherapeutic agen

52 decrease the recurrence or progression rate, intravesical chemotherapy or immunotherapy is also used.

53 Combination intravesical chemotherapy, targeted therapy, and drug de

54 munotherapy with intravesical BCG vaccine or intravesical chemotherapy.

55 Intravesical chitosan/IL-12 is a well-tolerated, effecti

56 nd no systemic absorption in the first human intravesical clinical trial.

57 dder and was observed in a patient receiving intravesical combination therapy.

58 xcitation of bladder reflexes in response to intravesical cytisine (100 muM) is blocked by systemic a

59 Intravesical delivery of LNP-dsP21-322-2'F into mouse bl

60 -322-2'F) into lipid nanoparticles (LNP) for intravesical delivery.

61 Intravesical docetaxel exhibited minimal toxicity and no

62 of OxoM (0.01-5 microg/kg) did not mimic the intravesical effects on voiding frequency.

63 Intravesical gemcitabine has shown some promising result

64 Eligible patients received two courses of intravesical gemcitabine twice weekly at a dose of 2,000

65 Intravesical gemcitabine, at doses up to 2 g/wk, is well

66 ted in TRPV1-/- mice in which sensitivity to intravesical hydrochloric acid (50 mm) and capsaicin (10

67 In clinical practice, intravesical IFN-alpha 2B (50 million units (MU)/dose) w

68 , mucoadhesive polysaccharide, could improve intravesical IL-12 delivery and provide an effective and

69 Unfortunately, intravesical IL-12 did not show antitumor efficacy in a

70 (NMIBC) is a highly recurrent tumor despite intravesical immunotherapy instillation with the bacillu

71 d urinary bladders underwent a new method of intravesical implantation of the transplant ureter.

72 Intravesical infusion of 0.1% acetic acid induced bladde

73 asation in the bladder or urethra induced by intravesical infusion of 0.25% acetic acid.

74 vely new drugs in the field, administered as intravesical injection and instillation, respectively.

75 These effects were blocked by intravesical injection of 5 muM atropine methyl nitrate

76 gement, medications, intravaginal pessaries, intravesical injection of botulinum toxin, percutaneous

77 rats bearing either bladder cancer (*IUdR by intravesical injection), brain gliosarcomas (intratumora

78 Infections were induced in female mice by intravesical inoculation with Escherichia coli, and the

79 ladder and kidney infections after receiving intravesical inoculation with uropathogenic Escherichia

80 Intravesical instillation of Ad5CMV-p53 is safe, feasibl

81 Intravesical instillation of bacterial lipopolysaccharid

82 on control anaesthetized rats revealed that intravesical instillation of bradykinin activated the mi

83 For superficial disease, intravesical instillation of chemotherapeutic agents aft

84 al resection of the tumor with perioperative intravesical instillation of chemotherapy strongly sugge

85 Intravesical instillation of small interfering RNA-conta

86 ow available, including extended release and intravesical instillation.

87 On a 28-day cycle, intravesical instillations of INGN 201 (Ad5CMV-p53) were

88 ients were randomly assigned for 16 adjuvant intravesical instillations with KLH after preimmunizatio

89 ients were randomly assigned for 11 adjuvant intravesical instillations with MM.

90 The intravesical method has been validated and is considered

91 lume needed to accurately measure IAP by the intravesical method in children is 3 mL.

92 stillation volume for IAP measurement by the intravesical method in children.

93 Electromotive intravesical mitomycin C as well as local microwave hype

94 view and meta-analysis is to determine if an intravesical or extravesical anastomosis in kidney trans

95 Intravesical or transdermal electrical stimulation, sacr

96 l role in the control of micturition because intravesical perfusion of apyrase or the ecto-ATPase inh

97 Intravesical perfusion of the ATP diphosphohydrolase apy

98 dysfunctional (decompensated), showing high intravesical pressure, large residual urine volume, and

99 Prostatic ultrasound measures such as the intravesical prostatic protrusion may be useful in couns

100 HG BCG-refractory or relapsed NMIBC received intravesical rAd-IFNalpha/Syn3 (randomly assigned 1:1 to

101 der distension (UBD) in rats pretreated with intravesical resiniferatoxin (RTX, 10(-7)M).

102 The intravesical route is still in the investigational phase

103 e results of our study provide evidence that intravesical RTX reduces the effects of viscerovisceral

104 ometrograms under urethane anesthesia during intravesical saline infusion exhibited intercontraction

105 CF) (1-100 mum, intravesically), or by using intravesical small interfering RNA, increased the interv

106 Multiple intravesical therapies have been used in this BCG failur

107 Response rates to second-line intravesical therapies range from 20% to 40%.

108 nvasive tumors permits appropriate timing of intravesical therapy and radical cystectomy.

109 cell bladder carcinoma who experienced prior intravesical therapy failure were studied.

110 cillus Calmette-Guerin is the most effective intravesical therapy for the treatment of superficial bl

111 diotherapy alone does not appear superior to intravesical therapy in NMIBC, at least one series with

112 Although Bacillus Calmette-Guerin (BCG) intravesical therapy is a standard treatment for bladder

113 on, nested variant, and other rare variants, intravesical therapy is an option based on standard risk

114 Intravesical therapy is utilized both as a one-time peri

115 arch has focused on improving and optimizing intravesical therapy to reduce tumor recurrence and prog

116 All patients who receive intravesical therapy with bacille Calmette-Guerin should

117 ndard therapeutic resection (with or without intravesical therapy), the superficial bladder tumor rec

118 thelial cell carcinoma (early cystectomy vs. intravesical therapy).

119 Intravesical treatment is used for carcinoma in situ and

120 hotopic bladder tumors were cured after four intravesical treatments with chitosan/IL-12.

121 urable and provided complete protection from intravesical tumor rechallenge.

122 in 16 piglets (32 kidneys) by unroofing the intravesical ureter and subsequently instilling a broth

123 Intravesical vanilloid (capsaicin or resiniferatoxin) ad

124 studies have demonstrated the feasibility of intravesical viral-mediated gene therapy.